Cabaletta Bio (CABA) is back in focus after a cluster of insider share purchases coinciding with fresh FDA clearance to use automated manufacturing platforms for its investigational CAR T cell therapy ...
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate ...
The chimeric antigen receptor T-cell therapy (CAR T) from Cabaletta Bio has already been cleared for trials in systemic lupus erythematosus, myositis, and systemic sclerosis. “While we remain on track ...
Starlyn Caba played in just 38 Dominican Summer League games last season, but he quickly made a strong impression. The slick-fielding, switch-hitting shortstop hit .301/.423/.346 with just 16 ...
PHILADELPHIA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...
) has been revised to $14.41 / share. This is an increase of 15.31% from the prior estimate of $12.50 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...
Single-A Jupiter transferred Caba from the 7-day injured list to the 60-day injured list May 7 with a left thumb sprain, Ely Sussman of Fish on First reports. Caba last played April 17 and will be ...
The Continental Automated Buildings Association (CABA) has unveiled a new brand identity, including the introduction of a new logo and descriptive tagline on the association's new Web site. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results